TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01871402
Drug: Vehicle Lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00018291
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00018291
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02214914
Drug: BI 11634 drinking solution
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02214914
Drug: BI 11634 tablet
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03117894
Drug: Betamethason 4 mg
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
Study: NCT03117894
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
Study: NCT03117894
Drug: Ondansetron 4 mg
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
Study: NCT03117894
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
Study: NCT01831323
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin
Study: NCT01831323
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine
Study: NCT00050817
Drug: clopidogrel (SR25990)
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02429973
Drug: Gemcitabine plus rapamycin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine and rapamycin given in combination
Study: NCT02165475
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02009865
Drug: Epanova
Normalized name: Epanova
DrugBank: Omega-3-carboxylic acids (DB09568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
Study: NCT02009865
Drug: Olive Oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
Study: NCT00960349
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
Study: NCT00960349
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
Study: NCT00960349
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Study: NCT00960349
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
Study: NCT02267213
Drug: Lipotecan
Normalized name: Lipotecan
DrugBank: Lipotecan (DB17385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
Study: NCT00193102
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide
Study: NCT00990314
Drug: Beraprost Sodium Modified Release
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02168855
Drug: active nicotine gum
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg, standard over-the-counter nicotine replacement therapy gum
Study: NCT00957749
Drug: cPMP
Normalized name: CPMP
DrugBank: Fosdenopterin (DB16628)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
Study: NCT01733485
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg/8 h for 5 days
Study: NCT02817698
Drug: cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
Study: NCT01433523
Drug: ALK HDM AIT 6 DU
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
Study: NCT01433523
Drug: ALK HDM AIT 12 DU
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
Study: NCT01675154
Drug: SLx-4090 placebo
Normalized name: SLx-4090
DrugBank: SLx-4090 (DB05678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given for 4 weeks
Study: NCT01675154
Drug: Orlistat Placebo
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 4 weeks
Study: NCT01675154
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given for 4 weeks
Study: NCT01675154
Drug: Slx-4090
Normalized name: SLx-4090
DrugBank: SLx-4090 (DB05678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given for 4 weeks
Study: NCT01877551
Drug: Tauroursodeoxycholic acid
Normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
Study: NCT01617772
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20 mg
Study: NCT02813356
Drug: naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non-interventional study where naloxegol is prescribed during normal clinical practice
Study: NCT01617772
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg L-carnitine
Study: NCT00532272
Drug: Letrozole ,Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
Study: NCT00005601
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02496767
Drug: Tirasemtiv
Normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005601
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005601
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005601
Drug: sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00376272
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03155035
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
Study: NCT02707315
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04395612
Drug: niraparib combined with brivanib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
Study: NCT04305496
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
Study: NCT04305496
Drug: Capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study: NCT02822092
Drug: Risperidone or Aripiprazole (patients only)
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inpatients deemed eligible for the study, we be put on open-label risperidone
Study: NCT03191097
Drug: Ingavirin
Normalized name: Ingavirin
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
Study: NCT00091572
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
Study: NCT00091572
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
Study: NCT04395612
Drug: niraparib combined with toripalimab
Normalized name: Toripalimab
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
Study: NCT00895076
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iontophoretic patch and injection
Study: NCT02824536
Drug: 10-1074
Normalized name: Anti-hiv-1 human monoclonal antibody targeting v3 glycan supersite on the hiv-1 envelope protein (10-1074)
DrugBank: Zinlirvimab (DB18867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of 10-1074
Study: NCT01695330
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
Study: NCT04172805
Drug: anlotinib and toripalimab
Normalized name: Toripalimab
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
Study: NCT01605760
Drug: immunotherapy Staloral
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
Study: NCT04658823
Drug: HOV-12020 (Palm tocotrienols complex)
Normalized name: HOVENIA DULCIS WHOLE
DrugBank: HOV-12020 (DB17976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
Study: NCT02409407
Drug: Misoprostol , Prostaglandins E1 analogue
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00637377
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Study: NCT02673723
Drug: Docozine
Normalized name: chlorpromazine hydrochloride Oral Solution [Dozine]
DrugBank: Promazine (DB00420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
Study: NCT01490125
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
Study: NCT03506802
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03506802
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03506802
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT00884676
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle.
Study: NCT00884676
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
Study: NCT02673723
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The same amount of saline is given for 10 seconds after surface anesthesia
Study: NCT01779596
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01990755
Drug: CBT + OLANZAPINE
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
Study: NCT01990755
Drug: delorazepam
Normalized name: Delorazepam
DrugBank: Delorazepam (DB01511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
Study: NCT00869219
Drug: Nevanac
Normalized name: Nevanac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop of NEVANAC at random eye
Study: NCT00869219
Drug: Acular LS
Normalized name: Acular LS
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of Acular LS
Study: NCT03259672
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane was used as a maintenance anesthetic agent.
Study: NCT02581124
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00444964
Drug: Nutropin AQ
Normalized name: Nutropin AQ
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0125 mg/kg/day
Study: NCT02332889
Drug: Decitabine and Hiltonol
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
Study: NCT03259672
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane was used as a maintenance anesthetic agent.
Study: NCT02056379
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
Study: NCT02056379
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
Study: NCT03507699
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered IV at a dose of 3mg/kg every 2 weeks
Study: NCT03507699
Drug: Ipilimumab Injection [Yervoy]
Normalized name: ipilimumab Injection [Yervoy]
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered IV at a dose of 1mg/kg every 6 weeks
Study: NCT03507699
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
Study: NCT00034346
Drug: ABX-EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034346
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00034346
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04251871
Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules
Normalized name: lopinavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.
Study: NCT04251871
Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Study: NCT03300570
Drug: Dolcanatide
Normalized name: Dolcanatide
DrugBank: Dolcanatide (DB13112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01491074
Drug: Tocilizumab 280 mg
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
Study: NCT01491074
Drug: NaCl 0.9% 100 ml
Normalized name: magnesium sulfate 6 g added to NaCl 0.9% 100 mL intravenous solution
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo